Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10065


The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.


Inclusion Criteria: - Women 18-70 with unilateral stage I or II BCRL - Volume difference of at least 300 mL between the normal and lymphedematous limb based on perometry evaluation - BMI of 18-30 - No current evidence of breast cancer - At least 6 months postop from axillary lymph node dissection Exclusion Criteria: - Bilateral lymphedema or history of bilateral axillary lymph node dissection - Recent history of cellulitis in the affected extremity (within last 3 months) - Recurrent breast cancer or other malignancy - Current (within last month) use of chemotherapy for breast or other malignancy - Current (within last 3 months) use of radiation for breast or other malignancy - Recent (within last month) or current intensive MLD and/or short stretch bandage use - Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months) - Pregnant or nursing (lactating) women - Stage III lymphedema - Patients that take acetaminophen (paracetamol) chronically, i.e. more than 1 g/day for more than 3 out of 7 days, or more than 2 g/ day for more than 1 day out of 7 days - Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer - History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. monoclonal antibodies, polyclonal gamma globulin, polysorbates).



Primary Contact:

Principal Investigator
Babak Mehara, MD
Memorial Sloan Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10065
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.